Cargando…
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798/ https://www.ncbi.nlm.nih.gov/pubmed/36029565 http://dx.doi.org/10.1016/j.breast.2022.08.002 |
| _version_ | 1784779567914811392 |
|---|---|
| author | Sim, Sung Hoon Kim, Jeong Eun Kim, Min Hwan Park, Yeon Hee Kim, Jee Hyun Suh, Koung Jin Koh, Su-Jin Park, Kyong Hwa Kang, Myoung Joo Ahn, Mi Sun Lee, Kyoung Eun Kim, Hee-Jun Ahn, Hee Kyung Kim, Han Jo Park, Keon Uk Byun, Jae Ho Park, Jin Hyun Lee, Gyeong-Won Lee, Keun Seok Sohn, Joohyuk Jung, Kyung Hae Park, In Hae |
| author_facet | Sim, Sung Hoon Kim, Jeong Eun Kim, Min Hwan Park, Yeon Hee Kim, Jee Hyun Suh, Koung Jin Koh, Su-Jin Park, Kyong Hwa Kang, Myoung Joo Ahn, Mi Sun Lee, Kyoung Eun Kim, Hee-Jun Ahn, Hee Kyung Kim, Han Jo Park, Keon Uk Byun, Jae Ho Park, Jin Hyun Lee, Gyeong-Won Lee, Keun Seok Sohn, Joohyuk Jung, Kyung Hae Park, In Hae |
| author_sort | Sim, Sung Hoon |
| collection | PubMed |
| description | We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. |
| format | Online Article Text |
| id | pubmed-9429798 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94297982022-09-01 Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) Sim, Sung Hoon Kim, Jeong Eun Kim, Min Hwan Park, Yeon Hee Kim, Jee Hyun Suh, Koung Jin Koh, Su-Jin Park, Kyong Hwa Kang, Myoung Joo Ahn, Mi Sun Lee, Kyoung Eun Kim, Hee-Jun Ahn, Hee Kyung Kim, Han Jo Park, Keon Uk Byun, Jae Ho Park, Jin Hyun Lee, Gyeong-Won Lee, Keun Seok Sohn, Joohyuk Jung, Kyung Hae Park, In Hae Breast Original Article We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. Elsevier 2022-08-17 /pmc/articles/PMC9429798/ /pubmed/36029565 http://dx.doi.org/10.1016/j.breast.2022.08.002 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Original Article Sim, Sung Hoon Kim, Jeong Eun Kim, Min Hwan Park, Yeon Hee Kim, Jee Hyun Suh, Koung Jin Koh, Su-Jin Park, Kyong Hwa Kang, Myoung Joo Ahn, Mi Sun Lee, Kyoung Eun Kim, Hee-Jun Ahn, Hee Kyung Kim, Han Jo Park, Keon Uk Byun, Jae Ho Park, Jin Hyun Lee, Gyeong-Won Lee, Keun Seok Sohn, Joohyuk Jung, Kyung Hae Park, In Hae Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| title | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| title_full | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| title_fullStr | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| title_full_unstemmed | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| title_short | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| title_sort | phase ii study to investigate the efficacy of trastuzumab biosimilar (herzuma®) plus treatment of physician's choice (tpc) in patients with heavily pretreated her-2+ metastatic breast cancer (kcsg br 18–14/km10b) |
| topic | Original Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798/ https://www.ncbi.nlm.nih.gov/pubmed/36029565 http://dx.doi.org/10.1016/j.breast.2022.08.002 |
| work_keys_str_mv | AT simsunghoon phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kimjeongeun phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kimminhwan phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT parkyeonhee phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kimjeehyun phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT suhkoungjin phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kohsujin phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT parkkyonghwa phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kangmyoungjoo phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT ahnmisun phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT leekyoungeun phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kimheejun phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT ahnheekyung phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT kimhanjo phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT parkkeonuk phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT byunjaeho phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT parkjinhyun phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT leegyeongwon phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT leekeunseok phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT sohnjoohyuk phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT jungkyunghae phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b AT parkinhae phaseiistudytoinvestigatetheefficacyoftrastuzumabbiosimilarherzumaplustreatmentofphysicianschoicetpcinpatientswithheavilypretreatedher2metastaticbreastcancerkcsgbr1814km10b |